Investigation of the impact of an ADCY2 polymorphism as a predictive biomarker in bipolar disorder, suicide tendency and response to lithium carbonate therapy: the first report from Iran.
Sara Sadat Aghabozorg AfjehJamal ShamsSafar HamedniaBehzad BoshehriAmir OlfatMir Davood OmraniPublished in: Pharmacogenomics (2020)
High rates of mortality due to both suicide and medical comorbidities in bipolar patients can be decreased through the administration of lithium, which affects the cerebral endothelium as well as neurons. To investigate the role of ADCY2 in risk of bipolar disorder, we genotyped the ADCY2 rs2290910 in bipolar patients and healthy controls using amplification refractory mutation system PCR. This polymorphism was associated with risk of bipolar disorder (odds ratio [OR]: 0.430; 95% CI: 0.296-0.624; p = 0.001). The C allele was more frequent in suicide ideation group compared other groups (OR: 2.7; 95% CI: 1.386-5.302; p = 0.004). The T allele was more frequent in suicide attempt group compared with suicide ideation group (OR: 0.238; 95% CI: 0.111-0.509; p = 0.001).
Keyphrases
- bipolar disorder
- major depressive disorder
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- depressive symptoms
- healthcare
- peritoneal dialysis
- nitric oxide
- cardiovascular disease
- coronary artery disease
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- cardiovascular events
- nucleic acid